We thank John Olsen (Wisconsin Department of Natural Resources), Tom Cooley, Daniel O'Brien and Steve Schmitt (Michigan Department of Natural Resources) and Dr. Daniel Walsh (USGS National Wildlife Health Center) for assistance with tissue acquisition. We also thank the Wisconsin State Laboratory of Hygiene for diagnostic testing services, and Dr. Tonie Rocke and her staff (USGS National Wildlife Health Center) for use of equipment. Any use of trade, product, or firm names is for descriptive purposes only and does not imply endorsement by the U.S. Government.

Animal lavoro condotto presso l&#39;USGS National Wildlife Health Center è stata eseguita in accordo con l&#39;Ufficio NIH di linee guida Laboratory Animal Welfare e sotto la cura degli animali istituzionale e comitato uso protocollo # EP080716. I tessuti di animali cacciatori-raccolta erano doni del Wisconsin o Michigan dipartimenti delle risorse naturali. 1. Soluzione Preparazione NOTA: Le soluzioni elencate di seguito sono necessari per la preparazione del substrato test CER nella Sezione 2 sotto. Preparare ciascuna di queste soluzioni di elevate soluzioni concentrazione azionari; Le concentrazioni consigliate per soluzioni madre sarà dato in parentesi dopo ogni rispettivo nome chimico elencato. Preparare tutte le soluzioni fresche sulla preparazione del substrato e conservare a 4 ° C fino al momento dell&#39;utilizzo. <ol><li> Per tampone di lisi, preparare una soluzione delle seguenti in Tris 10 mM, pH 7.5 (1 M Tris, pH 7.5 soluzione madre consigliato): 100 mm scloruro di odium (NaCl, 1 M soluzione madre), 10 mM di acido etilendiamminotetraacetico (EDTA, EDTA 500 mm, pH 8.0 soluzione madre), 0,5% NP-40 (10% soluzione madre), 0,5% desossicolato (DOC, 10% soluzione madre ). </li><li> Per buffer di conversione, preparare una soluzione di 0,05% sodio dodecil solfato (SDS, 10% soluzione madre) e 0,5% Triton X-100 (10% soluzione madre) in 1 tampone fosfato salino (PBS, 10, pH 7.4 soluzione stock). </li><li> Per le soluzioni caotropici, preparare due 3 M soluzioni di guanidina cloridrato (GdnHCl, 8 m stock) in 1x PBS (10x soluzione madre). Regolare il pH di una delle soluzioni di 3,5 ± 0,05 con acido cloridrico concentrato (HCl). Verificare che il pH della seconda soluzione rimane a pH 7,4 ± 0,05 e regolare utilizzando idrossido concentrato HCl o di sodio (NaOH) se necessario. </li></ol> 2. Preparare CER Assay substrato Pairs <ol><li> Ottenere tessuto cerebrale sano, non-TSE-infettati da specie di interesse e preparare un volume peso-per-10%(W / v) omogenato in tampone di lisi utilizzando uno dei seguenti metodi: Dounce, branello-mulino, o mortaio e pestello omogeneizzazione. Ulteriori definire risultante omogenati sottoponendoli a siringa e ago omogeneizzazione, usando aghi di calibro crescente fino substrato può essere aspirato ed espulsa con facilità attraverso un ago di siringa G 27. <ol><li> Per sottofondi preparati da roditori e altri piccoli mammiferi, omogeneizzare tutto il cervello (s); per substrati preparati da grandi mammiferi, utilizzare OBEX (tronco encefalico) tessuto da preparare omogeneizzati. Quando si seleziona la quantità di omogenato cerebrale, preparare non più del 50% della capacità della centrifuga utilizzata per precipitazione delle proteine ​​nel passo 2.6. </li><li> Se la qualità del tessuto cerebrale acquisita è discutibile, valutare i livelli di PrP C da SDS-PAGE 16 e immunoblot 17 prima del substrato di preparazione. </li></ol></li><li> Dividere omogenato cervello in due volumi uguali a tubi conici di plastica etichettati separati. Aggiungi GdnHCl (3 M soluzioni in 1 PBS) a pH 3,5 o 7,4 a ciascuna provetta in un rapporto 1: 1 volume di omogenato cerebrale. </li><li> Controllare i valori di pH delle due soluzioni. Regolare il pH del pH 3.5 ± substrato a pH 0,05 con HCl concentrato. Assicurarsi che il pH del altro substrato rimane a pH 7,4 ± 0,05 e regolare il pH se necessario con HCl o NaOH come necessario. Evitare di superamento dei valori di pH da giudiziosa aggiunta di acido o di base. </li><li> Ruotare soluzioni in un mixer end-over-end a temperatura ambiente (RT) per 5 ore. </li><li> Precipitato proteico aggiungendo quattro volumi di metanolo alle soluzioni substrato in ogni provetta conica, vortex per miscelare bene, e incubare a -20 ° C per 16-18 ore. </li><li> Campioni di sedimento di centrifugazione a 13.000 xg per 30 min a 4 ° C. Decantare con cautela e scartare il surnatante e lasciare evaporare il metanolo dai pellet. Utilizzare applicatori con punta di cotone per aiutare ad assorbire metanolo aggrappato alla parte interna del tubo. Non permettere pellets di over-dry e una volta metanolo non è più visibile, procedere al passo successivo. </li><li> Pellets proteine ​​Risospendere in tampone di conversione. Utilizzare una quantità di tampone di conversione pari alla quantità di omogenato cerebrale materiale di partenza erogato in ogni provetta nel passo 2.2. NOTA: E &#39;fondamentale che il buffer di conversione usato per risospendere pellet di proteine ​​sia da pH 3,5 e preparati substrato 7,4-trattati è la soluzione di cui al precedente punto 1.2 (che contiene bassi livelli di detersivi e un pH fisiologico). </li><li> Soluzioni brevemente agli ultrasuoni substrato in un sonicatore cuphorn (10 sec al ~ 30% di potenza massima), aliquota in 0,5-1,0 ml di volume in etichetta 1,5 ml microprovette. Eseguire un immunoblot controllo di qualità (passo 2.9) su un&#39;aliquota di ciascun substrato. Conservare le altre aliquote a -80 ° C fino al momento di effettuare test CER (sezione 4). </li><li> Eseguire il controllo della qualità su coppie substrato CER prima dell&#39;uso (Figura 2). Questi passaggi assicurano che substrati CER saranno provide risultati ottimali in studi di conversione. <ol><li> Garantire quantità comparabili di PrP C nei due substrati. Confronta i livelli di PrP in 10-25 ml di ogni substrato mediante SDS-PAGE 16 e immunoblotting 17. Se i livelli di proteine ​​nel pH 7.4 e 3.5 supporti si trovano a circa il 10% di ogni altro, le coppie substrato sono appropriati per l&#39;utilizzo in studi CER. NOTA: Le immunoblots PrP non dovrebbero mostrare la prova di un&#39;eccessiva degradazione PrP C. L&#39;immunoreattività PrP dovrebbe essere principalmente&gt; 20 kDa. Bands meno di questa massa molecolare possono essere prodotti di degradazione. Modelli banding dovrebbero essere più o meno equivalente tra coppie substrato. </li><li> Come la PrP C in entrambi i substrati dovrebbe essere sensibile PK, trattare 10-25 microlitri di ciascun substrato con PK ad una concentrazione finale di 100 mg / ml e digerire campioni a 1,000 rpm a 37 ° C per 1 ora in termo-shaker. Valutare qualsiasi segnale PrP rimanente SDS-PAGE 16 e immunoblotting 17.Substrati con res PrP non sono adatti per l&#39;utilizzo in studi CER. </li></ol></li></ol> 3. Preparare TSE Agente Seeds <ol><li> Ottenere tessuto cerebrale TSE-infettati da specie di interesse e di preparare un 10% (w / v) omogeneizzato in 1x PBS pH 7.4 con le modalità di cui al punto 2.1. NOTA: Semi potrebbero essere ottenuti anche da altri tessuti infetti da TSE fuori del sistema nervoso centrale, tuttavia, l&#39;efficienza di conversione del cervello derivato substrati da semi derivati ​​da tessuti periferici TSE-infette non è ancora stata valutata sperimentalmente nella letteratura pubblicata. </li><li> Aliquota risultante omogeneizzato (s) in 100-300 volumi microlitri in 0,5 ml provette da microcentrifuga e conservare a -80 ° C fino al momento di eseguire il test CER. </li></ol> 4. CER Assay NOTA: Il test CER comporta aggiunta di una quantità relativamente piccola di PrP TSE (fornito nel &quot;seme&quot;) da una speciein un eccesso relativo di PrP C (fornito nel cervello non infette &quot;substrato&quot;) da un&#39;altra specie che è stato parzialmente denaturati a pH 3.5 o 7.4. Dopo un periodo di incubazione prolungato tremante, la conversione template-driven di PrP C da PrP TSE in ogni reazione è valutata dal segnale densitometrica di PrP res rimanente dopo PK digestione e la rilevazione immunoblot. Confrontando livelli res PrP nei substrati precedentemente denaturate a pH 3,5 contro 7,4 fornisce una misura della barriera di specie. Una panoramica sperimentale di questa procedura di analisi è fornito in Figura 1. <ol><li> Lentamente scongelare infetti coppie substrato CER (test richiede volumi uguali di substrati precedentemente denaturato sia a pH 3.5 e 7.4) e le soluzioni di semi TSE-infetti mettendoli sulla cima di un letto di ghiaccio (a circa 1 ora di tempo disgelo). </li><li> Una volta completamente scongelati, aspirare e poi espellere ogni soluzione substrato attraverso un27 G siringa più volte a ri-omogeneizzare. Brevemente agli ultrasuoni ogni soluzione seme TSE-infettati per 10 secondi al ~ 30% di potenza massima. Tenere tutte le soluzioni sul ghiaccio mentre si prepara reazioni di conversione. </li><li> Label 5 singoli, pareti sottili tubi basso legame PCR per agente TSE in fase di sperimentazione. </li><li> Preparare reazioni di conversione in questi tubi aggiungendo 5 ml di soluzione al 10% di semi TSE-infetta a 95 ml di (a) substrato CER preparati a pH 7,4 e (b) substrato CER preparati a pH 3,5. <ol><li> Per ogni campione sperimentale, preparare reazioni parallele a coppie substrato CER precedentemente denaturato sia a pH 3,5 e 7,4. </li><li> Ottimizzare i rapporti di TSE seme agente per substrato cervello infetto attraverso la determinazione empirica. Seme Comune: rapporti substrato impiegati mantengono un volume totale di reazione di 100 ml e comprendono 1:99 microlitri, 2:98 e 5:95 ul ul. Per la maggior parte delle applicazioni, il seme 5:95 microlitri: rapporto volume del substrato è adeguato ed è quello che si presenta in thè il protocollo. </li></ol></li><li> Preparare tre campioni di controllo per agente TSE in fase di test nel modo seguente: (a) aggiungere 5 ml di soluzione al 10% di semi di TSE-infetta al buffer di conversione 95 microlitri come controllo per ingresso res PrP; aggiungere buffer di conversione 5 ml a 95 ml di substrato preparato a (b) pH 3.5 (c), pH 7,4 come controlli per non-specifico, la conversione non su modelli. </li><li> Brevemente vortice ogni campione nella sua provetta PCR chiuso mescolare semi e substrato bene. Seguire con un impulso momentaneo in una bassa velocità da banco mini-centrifuga per rimuovere qualsiasi volume della miscela di reazione intrappolato nel coperchio provetta PCR. </li><li> Caricare i campioni in tubi PCR singolarmente etichettati in un banco top termo-shaker attrezzato per accettare provette PCR. Agitare campioni a 1,000 rpm a 37 ° C per 24 ore. </li><li> Dopo agitazione, aggiungere sarcosile ad una concentrazione finale del 2% (w / v) e PK ad una concentrazione finale di 100 mg / ml. Campioni Digest a 1,000 rpm a 37 ° C per 1 ora in termo-shaker. NOTE: aggiunta di sarcosile campioni aiuti post-conversione in PK digestione di PrP C. Segnali positivi falsi in campioni non teste di serie (punto 4.5) sono virtualmente eliminati con l&#39;aggiunta di sarcosile. </li><li> Aggiungere tampone campione SDS-PAGE, campioni di calore a 95 ° C per 5 minuti e risolvere rimanenti PrP res in ciascun campione mediante SDS-PAGE seguita da immunoblotting 16 17. NOTA: Dopo l&#39;aggiunta di tampone campione e riscaldamento, i campioni possono essere immediatamente elaborato o campioni possono essere conservati a -20 ° C o -80 ° C prima di immunoblotting. Tutti i dati qui presentati sono stati generati utilizzando i sistemi di gel e di trasferimento Novex NuPAGE. I singoli campioni del test CER sono stati trattati con il tampone e la riduzione dell&#39;agente secondo le istruzioni del produttore. I campioni sono stati successivamente riscaldati a 95 ° C per 5 min e 30 microlitri di ciascun campione sono stati caricati in un 12% bis-tris gel prefabbricati. </li><li> Calcolare il rapporto efficienza di conversione (CER) come misurabarriera di specie. Misura i livelli di res PrP di densitometria 17 e dividono la densità totale del campione pH 7,4 da quella del campione di 3,5 pH. Moltiplicare per 100 per produrre una percentuale. </li><li> Compilare i dati da repliche sperimentali indipendenti di generare una media CER ± deviazione standard per una specie con un determinato agente TSE. </li></ol>

<ol>
	<li>Colby, D. W., Prions Prusiner, S. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Cold Spring Harb Perspect Biol. 3 (1), a006833 (2011).</li><li>Hill, A. F., Collinge, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prion+strains+and+species+barriers.">Prion strains and species barriers.</a> Contrib Microbiol. 11, 33-49 (2004).</li><li>Scott, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Transgenic+mice+expressing+hamster+prion+protein+produce+species-specific+scrapie+infectivity+and+amyloid+plaques.">Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques.</a> Cell. 59 (5), 847-857 (1989).</li><li>Prusiner, S. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Transgenetic+Studies+Implicate+Interactions+between+Homologous+Prp+Isoforms+in+Scrapie+Prion+Replication.">Transgenetic Studies Implicate Interactions between Homologous Prp Isoforms in Scrapie Prion Replication.</a> Cell. 63, 673-686 (1990).</li><li>Telling, G. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prion+Propagation+in+Mice+Expressing+Human+and+Chimeric+Prp+Transgenes+Implicates+the+Interaction+of+Cellular+Prp+with+Another+Protein.">Prion Propagation in Mice Expressing Human and Chimeric Prp Transgenes Implicates the Interaction of Cellular Prp with Another Protein.</a> Cell. 83, 79-90 (1995).</li><li>Hill, A. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+same+prion+strain+causes+vCJD+and+BSE.">The same prion strain causes vCJD and BSE.</a> Nature. 389 (6650), 448-450 (1997).</li><li>Torres, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Elements+modulating+the+prion+species+barrier+and+its+passage+consequences.">Elements modulating the prion species barrier and its passage consequences.</a> PLoS One. 9 (3), e89722 (2014).</li><li>Groschup, M. H., Buschmann, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rodent+models+for+prion+diseases.">Rodent models for prion diseases.</a> Vet Res. 39 (4), 32 (2008).</li><li>Korth, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Abbreviated+incubation+times+for+human+prions+in+mice+expressing+a+chimeric+mouse-human+prion+protein+transgene.">Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene.</a> Proc Natl Acad Sci U S A. 100 (8), 4784-4789 (2003).</li><li>Kocisko, D. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Species+specificity+in+the+cell-free+conversion+of+prion+protein+to+protease-resistant+forms:+a+model+for+the+scrapie+species+barrier.">Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier.</a> Proc Natl Acad Sci U S A. 92 (9), 3923-3927 (1995).</li><li>Raymond, G. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evidence+of+a+molecular+barrier+limiting+susceptibility+of+humans,+cattle+and+sheep+to+chronic+wasting+disease.">Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease.</a> EMBO J. 19 (7), 4425-4430 (2000).</li><li>Fernandez-Borges, N., de Castro, J., Castilla, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vitro+studies+of+the+transmission+barrier.">In vitro studies of the transmission barrier.</a> Prion. 3 (4), 220-223 (2009).</li><li>Zou, W. Q., Cashman, N. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Acidic+pH+and+detergents+enhance+in+vitro+conversion+of+human+brain+PrPC+to+a+PrPSc-like+form.">Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form.</a> J Biol Chem. 277 (46), 43942-43947 (2002).</li><li>Li, L., Coulthart, M. B., Balachandran, A., Chakrabartty, A., Cashman, N. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Species+barriers+for+chronic+wasting+disease+by+in+vitro+conversion+of+prion+protein.">Species barriers for chronic wasting disease by in vitro conversion of prion protein.</a> Biochem Biophys Res Commun. 364 (4), 796-800 (2007).</li><li>Morawski, A. R., Carlson, C. M., Chang, H., Johnson, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vitro+prion+protein+conversion+suggests+risk+of+bighorn+sheep+(Ovis+canadensis)+to+transmissible+spongiform+encephalopathies.">In vitro prion protein conversion suggests risk of bighorn sheep (Ovis canadensis) to transmissible spongiform encephalopathies.</a> BMC Vet Res. 9, 157 (2013).</li><li>Chandler, R. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Encephalopathy+in+mice+produced+by+inoculation+with+scrapie+brain+material.">Encephalopathy in mice produced by inoculation with scrapie brain material.</a> Lancet. 1 (7191), 1378-1379 (1961).</li><li>Browning, S. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Transmission+of+prions+from+mule+deer+and+elk+with+chronic+wasting+disease+to+transgenic+mice+expressing+cervid+PrP.">Transmission of prions from mule deer and elk with chronic wasting disease to transgenic mice expressing cervid PrP.</a> J Virol. 78 (23), 13345-13350 (2004).</li><li>Hadlow, W. J., Race, R. E., Kennedy, R. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Experimental+infection+of+sheep+and+goats+with+transmissible+mink+encephalopathy+virus.">Experimental infection of sheep and goats with transmissible mink encephalopathy virus.</a> Can J Vet Res. 51 (1), 135-144 (1987).</li><li>Rubenstein, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immune+surveillance+and+antigen+conformation+determines+humoral+immune+response+to+the+prion+protein+immunogen.">Immune surveillance and antigen conformation determines humoral immune response to the prion protein immunogen.</a> J Neurovirol. 5 (4), 401-413 (1999).</li><li>Castilla, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Crossing+the+species+barrier+by+PrP(Sc)+replication+in+vitro+generates+unique+infectious+prions.">Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions.</a> Cell. 134 (5), 757-768 (2008).</li><li>Kubista, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+real-time+polymerase+chain+reaction.">The real-time polymerase chain reaction.</a> Mol Aspects Med. 27, 95-125 (2006).</li><li>Atarashi, R., Sano, K., Satoh, K., Nishida, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Real-time+quaking-induced+conversion:+a+highly+sensitive+assay+for+prion+detection.">Real-time quaking-induced conversion: a highly sensitive assay for prion detection.</a> Prion. 5 (3), 150-153 (2011).</li><li>Ladner-Keay, C. L., Griffith, B. J., Wishart, D. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Shaking+Alone+Induces+De+Novo+Conversion+of+Recombinant+Prion+Proteins+to+beta-Sheet+Rich+Oligomers+and+Fibrils.">Shaking Alone Induces De Novo Conversion of Recombinant Prion Proteins to beta-Sheet Rich Oligomers and Fibrils.</a> PLoS One. 9 (6), e98753 (2014).</li><li>Mathiason, C. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Susceptibility+of+domestic+cats+to+chronic+wasting+disease.">Susceptibility of domestic cats to chronic wasting disease.</a> J Virol. 87 (4), 1947-1956 (2013).</li><li>Seelig, D. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lesion+Profiling+and+Subcellular+Prion+Localization+of+Cervid+Chronic+Wasting+Disease+in+Domestic+Cats.">Lesion Profiling and Subcellular Prion Localization of Cervid Chronic Wasting Disease in Domestic Cats.</a> Vet Pathol. , (2014).</li><li>Stewart, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genetic+predictions+of+prion+disease+susceptibility+in+carnivore+species+based+on+variability+of+the+prion+gene+coding+region.">Genetic predictions of prion disease susceptibility in carnivore species based on variability of the prion gene coding region.</a> PLoS One. 7 (12), e50623 (2012).</li><li>Russell, W. M., Burch, R. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> The Principles of Humane Experimental Technique. Metheun. , (1959).</li></ol>

The authors have nothing to disclose.

Per il completamento di questo protocollo, occorre prestare attenzione ai livelli PrP C nel tessuto cerebrale infetto usato per la preparazione del substrato (fase 2.1.2) e il seme al substrato rapporto per le reazioni di conversione (passo 4.4.2). Nella nostra esperienza, cervello possono essere estratte per uso come substrato CER dopo un sostanziale periodo post-mortem, purché PrP C è presente per immunoblotting (Figura 4). In effetti, alcuni autolisi è stato osservato nel cer...

Encefalopatie spongiformi trasmissibili (TSE, malattie prioniche) sono un gruppo di malattie neurodegenerative fatali con periodi di incubazione lunghi che interessano una varietà di animali ed esseri umani. L&#39;agente eziologico putativo di TSE comprende un isomero misfolded della proteina prionica host (PrP) che è in grado di auto-propagazione per conversione template-driven della forma cellulare normale PrP (PrP C) in una, associata malattia infettiva forma (PrP TSE) che si accumula nei tessuti del sistema nervoso centrale dell&#39;ospite infettato 1. Prioni mammiferi infettive in genere trasmettono da host-to-host in modo specifico per le specie, che ha dato origine al concetto di &quot;TSE specie barriera&quot; limitare gli eventi di trasmissione interspecie 2. I fattori biologici della barriera prione specie non sono ben compresi. Sequenza aminoacidica somiglianza tra il infettiva PrP TSE e l&#39;host PrP C cUn&#39;influenza fortemente se conversione avviene 3-5, ma rimane insufficiente per spiegare tutti gli eventi di trasmissione dei prioni osservati in vivo 6,7. Così, la caratterizzazione delle barriere di specie TSE ha largamente invocato studi di provocazione animale: esporre animali ingenui da una determinata specie di prioni da un altro e misurando il tempo di incubazione risultante per l&#39;insorgenza della malattia e il tasso di attacco come indicatori di efficienza di trasmissione. I topi che esprimono PrP C da specie eterologhe sono utilizzati anche per questo tipo di studio 8. I costi associati alla produzione di topo transgenico e biotest prioni prolungati, così come le considerazioni etiche di utilizzo degli animali, sono ostacoli alla ricerca sperimentale di TSE barriere di specie. Valutazione della barriera di specie umana di TSE si basa su topi ingegnerizzati per esprimere umana PrP C. Questi topi richiedono periodi di incubazione lunghi a soccombere alle TSE o modifiche al T umaniegli molecola PrP C umana per la malattia rapida insorgenza 9. Periodi di incubazione delle EST non umano in questi topi possono estendersi oltre la normale durata di vita del mouse facendo interpretazione dei risultati negativi difficili. I primati non umani sono stati utilizzati anche come proxy per lo studio delle barriere di specie umane, ma questi studi sono irto le stesse sfide degli altri tipi di sperimentazione animale e primati non umani non può ricapitolare precisamente malattia procede nell&#39;ospite umano. Analisi su animali rimangono il metodo &quot;gold standard&quot; per misurare la suscettibilità di una specie di TSE, ma gli ostacoli, i costi e l&#39;etica di questi studi su animali vivi hanno costretto indagini alternative. Un certo numero di saggi in vitro, basati sulla valutazione della conversione di ospitante PrP C ad una proteinasi K (PK) Stato -resistenti (res PrP) quando seminato da PrP TSE, sono stati sviluppati e utilizzati per studiare TSE spECIES barriere 10-12. Esempi di saggi in vitro includono test cell-free di conversione, proteine ​​misfolding di amplificazione ciclica (PMCA), e il rapporto di efficienza di conversione (CER) dosaggio 10-14. Anche se nessuno di questi test tiene conto di fattori periferici coinvolti in barriere di specie dopo l&#39;infezione naturale, tutto può essere utile per identificare gli host potenzialmente sensibili per le TSE. Qui vi presentiamo il protocollo per il test CER, in cui due substrati denaturati PrP C derivati ​​da normali omogenati cerebrali sono utilizzati in reazioni di conversione prione banco (Figura 1) 13. PrP C nel substrato denaturato a pH 7,4 può essere convertito solo res PrP da PrP TSE seminate nella reazione in assenza di una barriera di specie 14. Al contrario, denaturazione di PrP C in altro substrato a pH 3.5 permette di essere convertito PrP res seguente incubazionecon PrP TSE da qualsiasi specie e serve come controllo per la conversione. Il rapporto di conversione di PrP C res PrP in pH 7,4 substrato rispetto a quella del substrato pH 3.5 fornisce una misura della barriera di specie. Abbiamo scoperto che il test CER predice noto barriere di specie di topi di laboratorio per varie TSE e hanno utilizzato il test nel tentativo di prevedere la barriera di specie di numerose specie di mammiferi, tra cui pecore bighorn, alla malattia del dimagrimento cronico (CWD) e altre TSE 14, 15. Gli investigatori interessati in uno strumento che consenta il rapido screening delle TSE specie barriere o valutazione della conversione PrP C-to-PrP res troveranno questa metodologia utile.

<table border="0" cellpadding="0" cellspacing="0" width="944">
	<tbody>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Name of Material/ Equipment</td>
			<td style="width:205px;">Company</td>
			<td style="width:157px;">Catalog Number</td>
			<td style="width:287px;">Comments/Description</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">12% Bis-Tris SDS-PAGE gels</td>
			<td style="width:205px;">Life Technologies</td>
			<td style="width:157px;">NP0342</td>
			<td></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">0.5 mm zirconium oxide beads</td>
			<td style="width:205px;">Next Advance</td>
			<td style="width:157px;">ZROB05&#160;</td>
			<td style="width:287px;">Other varieties of beads are also effective</td>
		</tr>
		<tr height="66">
			<td height="66" style="height:66px;width:296px;">Antibodies</td>
			<td style="width:205px;">various suppliers</td>
			<td style="width:157px;"></td>
			<td style="width:287px;">Select appropriate primary and secondary antibodies for immunoblot detection of PrPres from species of interest</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Bead homogenizer</td>
			<td style="width:205px;">Next Advance</td>
			<td style="width:157px;">BBY24M</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Centrifuge&#160;</td>
			<td style="width:205px;">Beckman Coulter</td>
			<td style="width:157px;">369434</td>
			<td style="width:287px;">High speed with temperature control</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Conical tubes</td>
			<td style="width:205px;">any brand</td>
			<td style="width:157px;"></td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Cotton-tipped applicator</td>
			<td style="width:205px;">Uline</td>
			<td style="width:157px;">S-18991</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Cuphorn sonicator</td>
			<td style="width:205px;">Heat Systems-Ultrasonics</td>
			<td style="width:157px;">W-380</td>
			<td style="width:287px;">Heat Systems-Ultrasonics, Inc. is now Qsonica, LLC</td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;width:296px;">Densitometry software program</td>
			<td style="width:205px;">UVP</td>
			<td style="width:157px;">Vision Works LS Image Acquisition and Analysis software</td>
			<td style="width:287px;">Other programs, such as NIH ImageJ, will also work</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Dounce homogenizer</td>
			<td style="width:205px;">Kimble Chase</td>
			<td style="width:157px;">885300</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">End-over-end mixer</td>
			<td style="width:205px;">Labnet International</td>
			<td style="width:157px;">H5600</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Ethylenediaminetetra acetic acid</td>
			<td style="width:205px;">Boston Bioproducts</td>
			<td style="width:157px;">P-770</td>
			<td style="width:287px;">Hazardous chemical: eye irritation</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Guanidine hydrochloride, 8M</td>
			<td style="width:205px;">Thermo Fisher Scientific</td>
			<td style="width:157px;">24115</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity, skin irritation, eye irritation</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Heating block</td>
			<td style="width:205px;">Fisher Scientific</td>
			<td style="width:157px;">11-718</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Hydrochloric acid</td>
			<td style="width:205px;">Sigma-Aldrich&#160;</td>
			<td style="width:157px;">435570</td>
			<td style="width:287px;">Hazardous chemical: strong acid</td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;">Lithium dodecyl sulfate sample buffer, 4X</td>
			<td style="width:205px;">Life Technologies</td>
			<td style="width:157px;">NP0008</td>
			<td style="width:287px;">Hazardous chemical: skin &#38; respiratory irritation, serious eye damage, flammable solid</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">Methanol</td>
			<td style="width:205px;">Fisher Scientific</td>
			<td style="width:157px;">A454-4</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity, flammable liquid</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Microcentrifuge tubes</td>
			<td style="width:205px;">any brand</td>
			<td style="width:157px;"></td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;">Mini-centrifuge</td>
			<td style="width:205px;">Labnet International</td>
			<td style="width:157px;">C1301</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;">N-lauroyl-sarcosine (sarkosyl)</td>
			<td style="width:205px;">Sigma-Aldrich&#160;</td>
			<td style="width:157px;">L-5125</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity, skin irritation, eye damage</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Nonidet P-40</td>
			<td style="width:205px;">Amresco</td>
			<td style="width:157px;">M158</td>
			<td style="width:287px;">Hazardous chemical: skin irritation, eye damage</td>
		</tr>
		<tr height="63">
			<td height="63" style="height:63px;width:296px;">SDS-PAGE gel system</td>
			<td style="width:205px;">Life Technologies</td>
			<td style="width:157px;">NuPAGE electrophoresis system</td>
			<td style="width:287px;">Other SDS-PAGE systems will also work</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">PCR tubes (low-binding)</td>
			<td style="width:205px;">Axygen</td>
			<td style="width:157px;">PCR-02-L-C</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Pestle homogenizer</td>
			<td style="width:205px;">Fisher Scientific</td>
			<td style="width:157px;">03-392-106</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">pH meter</td>
			<td style="width:205px;">Sentron</td>
			<td style="width:157px;">SI600</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Polyvinyldifluoride membrane</td>
			<td style="width:205px;">Millipore</td>
			<td style="width:157px;">IPVH00010</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Proteinase K</td>
			<td style="width:205px;">Promega</td>
			<td style="width:157px;">V3021</td>
			<td style="width:287px;">Hazardous chemical: skin &#38; eye irritation, respiratory sensitisation, organ toxicity</td>
		</tr>
		<tr height="23">
			<td height="23" style="height:23px;width:296px;">Reducing agent for SDS-PAGE samples, 10X</td>
			<td style="width:205px;">Life Technologies</td>
			<td style="width:157px;">NP0009</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Sodium Chloride</td>
			<td style="width:205px;">Fisher Scientific</td>
			<td style="width:157px;">7647-14-5</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Sodium deoxycholate</td>
			<td style="width:205px;">Sigma-Aldrich&#160;</td>
			<td style="width:157px;">D6750</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Sodium dodecyl sulfate</td>
			<td style="width:205px;">Thermo Fisher Scientific</td>
			<td style="width:157px;">28364</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity, skin irritation, eye damage, flammable solid</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Sodium hydroxide</td>
			<td style="width:205px;">Sigma-Aldrich&#160;</td>
			<td style="width:157px;">S5881</td>
			<td style="width:287px;">Hazardous chemica; strong base</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Syringe</td>
			<td style="width:205px;">BD Biosciences</td>
			<td style="width:157px;">various</td>
			<td style="width:287px;">Use syringe size appropriate to volumes of substrate to be homogenized</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Syringe needles</td>
			<td style="width:205px;">BD Biosciences</td>
			<td style="width:157px;">various</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Thermoshaker (PCR tube shaker)</td>
			<td style="width:205px;">Hangzhou All Sheng Instruments</td>
			<td style="width:157px;">MS-100</td>
			<td style="width:287px;"></td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Tris base</td>
			<td style="width:205px;">Bio Basic&#160;</td>
			<td style="width:157px;">77-86-1</td>
			<td style="width:287px;">Hazardous chemical: skin, eye, respiratory irritation</td>
		</tr>
		<tr height="42">
			<td height="42" style="height:42px;width:296px;">Triton X-100</td>
			<td style="width:205px;">Integra Chemical Company</td>
			<td style="width:157px;">T756.30.30</td>
			<td style="width:287px;">Hazardous chemical: acute toxicity, eye irritation</td>
		</tr>
		<tr height="21">
			<td height="21" style="height:21px;width:296px;">Vortexer</td>
			<td style="width:205px;">Fisher Scientific</td>
			<td style="width:157px;">12-812</td>
			<td style="width:287px;"></td>
		</tr>
	</tbody>
</table>

assessing transmissible spongiform encephalopathy species barriers with an in vitro prion protein conversion assay

Studies to understanding interspecies transmission of transmissible spongiform encephalopathies (TSEs, prion diseases) are challenging in that they typically rely upon lengthy and costly in vivo animal challenge studies. A number of in vitro assays have been developed to aid in measuring prion species barriers, thereby reducing animal use and providing quicker results than animal bioassays. Here, we present the protocol for a rapid in vitro prion conversion assay called the conversion efficiency ratio (CER) assay. In this assay cellular prion protein (PrPC) from an uninfected host brain is denatured at both pH 7.4 and 3.5 to produce two substrates. When the pH 7.4 substrate is incubated with TSE agent, the amount of PrPC that converts to a proteinase K (PK)-resistant state is modulated by the original host&#8217;s species barrier to the TSE agent. In contrast, PrPC in the pH 3.5 substrate is misfolded by any TSE agent. By comparing the amount of PK-resistant prion protein in the two substrates, an assessment of the host&#8217;s species barrier can be made. We show that the CER assay correctly predicts known prion species barriers of laboratory mice and, as an example, show some preliminary results suggesting that bobcats (Lynx rufus) may be susceptible to white-tailed deer (Odocoileus virginianus) chronic wasting disease agent.

Uso di successo del dosaggio CER dipende in gran parte dalla qualità delle coppie substrato utilizzati nelle reazioni di conversione. Per questo motivo, secondo procedure per preparare CER coppie substrato, un immunoblot controllo di qualità deve essere eseguito (Figura 2). Per entrambi i substrati, dosaggio 10-25 ml per immunoblotting. PrP C dovrebbe essere facilmente rilevabile in ogni substrato e livelli di PrP C deve essere di circa la stessa tra i due. Immunoreattività sar?...

Watch this Scientific Journal Video about Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay at JoVE.com

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Measuring the barrier to the interspecies transmission of prion diseases is challenging and typically involves animal challenges or biochemical assays. Here, we present an in vitro prion protein conversion assay with the ability to predict species barriers.

Valutare l&#39;encefalopatia spongiforme trasmissibile Specie Barriere con un<em&gt; In Vitro</em&gt; Prion Protein Assay Conversion

Studies to understanding interspecies transmission of transmissible spongiform encephalopathies (TSEs, prion diseases) are challenging in that they ...

assessing-transmissible-spongiform-encephalopathy-species-barriers

Research

JoVE Journal

Medicine

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

7.7K Views.  USGS National Wildlife Health Center. Measuring the barrier to the interspecies transmission of prion diseases is challenging and typically involves animal challenges or biochemical assays. Here, we present an in vitro prion protein conversion assay with the ability to predict species barriers.

Video: Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Identification of biomarkers representing the evolution of the pathophysiology of Post Traumatic Stress Disorder (PTSD) is vitally important, not only for objective diagnosis but also for the evaluation of therapeutic efficacy and resilience to trauma. Ongoing research is directed at identifying molecular biomarkers for PTSD, including traumatic stress induced proteins, transcriptomes, genomic variances and genetic modulators, using biologic samples from subjects' blood, saliva, urine, and postmortem brain tissues. However, the correlation of these biomarker molecules in peripheral or postmortem samples to altered brain functions associated with psychiatric symptoms in PTSD remains unresolved. Here, we present an animal model of PTSD in which both peripheral blood and central brain biomarkers, as well as behavioral phenotype, can be collected and measured, thus providing the needed correlation of the central biomarkers of PTSD, which are mechanistic and pathognomonic but cannot be collected from people, with the peripheral biomarkers and behavioral phenotypes, which can.
Our animal model of PTSD employs restraint and tail shocks repeated for three continuous days - the inescapable tail-shock model (ITS) in rats. This ITS model mimics the pathophysiology of PTSD 17, 7, 4, 10. We and others have verified that the ITS model induces behavioral and neurobiological alterations similar to those found in PTSD subjects 17, 7, 10, 9. Specifically, these stressed rats exhibit (1) a delayed and exaggerated startle response appearing several days after stressor cessation, which given the compressed time scale of the rat's life compared to a humans, corresponds to the one to three months delay of symptoms in PTSD patients (DSM-IV-TR PTSD Criterian D/E 13), (2) enhanced plasma corticosterone (CORT) for several days, indicating compromise of the hypothalamopituitary axis (HPA), and (3) retarded body weight gain after stressor cessation, indicating dysfunction of metabolic regulation.
The experimental paradigms employed for this model are: (1) a learned helplessness paradigm in the rat assayed by measurement of acoustic startle response (ASR) and a charting of body mass; (2) microdissection of the rat brain into regions and nuclei; (3) enzyme-linked immunosorbent assay (ELISA) for blood levels of CORT; (4) a gene expression microarray plus related bioinformatics tools 18. This microarray, dubbed rMNChip, focuses on mitochondrial and mitochondria-related nuclear genes in the rat so as to specifically address the neuronal bioenergetics hypothesized to be involved in PTSD.

We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.

Biomarcatori in un modello animale per Rivelare correlati neurali, ematologiche, e comportamentali di PTSD

Identification of biomarkers representing the evolution of the pathophysiology of Post Traumatic Stress Disorder (PTSD) is vitally important, not only for ...

Ricerca

Medicina

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Fetal alcohol syndrome (FAS) is a severe manifestation of embryonic exposure to ethanol. It presents with characteristic defects to the face and organs, including mental retardation due to disordered and damaged brain development. Fetal alcohol spectrum disorder (FASD) is a term used to cover a continuum of birth defects that occur due to maternal alcohol consumption, and occurs in approximately 4% of children born in the United States. With 50% of child-bearing age women reporting consumption of alcohol, and half of all pregnancies being unplanned, unintentional exposure is a continuing issue2. In order to best understand the damage produced by ethanol, plus produce a model with which to test potential interventions, we developed a model of developmental ethanol exposure using the zebrafish embryo. Zebrafish are ideal for this kind of teratogen study3-8. Each pair lays hundreds of eggs, which can then be collected without harming the adult fish. The zebrafish embryo is transparent and can be readily imaged with any number of stains. Analysis of these embryos after exposure to ethanol at different doses and times of duration and application shows that the gross developmental defects produced by ethanol are consistent with the human birth defect. Described here are the basic techniques used to study and manipulate the zebrafish FAS model.

In order to understand the molecular mechanisms of the ethanol-induced developmental damage, we have developed a zebrafish model of ethanol exposure and are exploring the physical, cellular, and genetic alterations that occur after ethanol exposure1. We then seek to find potential interventions and rapidly test them in this animal model.

Valutare i cambiamenti teratogeni in un modello di Zebrafish di esposizione alcolica fetale

Fetal alcohol syndrome (FAS) is a severe manifestation of embryonic exposure to ethanol. It presents with characteristic defects to the face and organs, ...

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform PrPSc 1. PrPC is detergent-soluble and sensitive to proteinase K (PK)-digestion, whereas PrPSc forms detergent-insoluble aggregates and is partially resistant to PK2-6. The conversion of PrPC to PrPSc is known to involve a conformational transition of &alpha;-helical to &beta;-sheet structures of the protein. However, the in vivo pathway is still poorly understood. A tentative endogenous PrPSc, intermediate PrP* or "silent prion", has yet to be identified in the uninfected brain7.
Using a combination of biophysical and biochemical approaches, we identified insoluble PrPC aggregates (designated iPrPC) from uninfected mammalian brains and cultured neuronal cells8, 9. Here, we describe detailed procedures of these methods, including ultracentrifugation in detergent buffer, sucrose step gradient sedimentation, size exclusion chromatography, iPrP enrichment by gene 5 protein (g5p) that specifically bind to structurally altered PrP forms10, and PK-treatment. The combination of these approaches isolates not only insoluble PrPSc and PrPC aggregates but also soluble PrPC oligomers from the normal human brain. Since the protocols described here have been used to isolate both PrPSc from infected brains and iPrPC from uninfected brains, they provide us with an opportunity to compare differences in physicochemical features, neurotoxicity, and infectivity between the two isoforms. Such a study will greatly improve our understanding of the infectious proteinaceous pathogens. The physiology and pathophysiology of iPrPC are unclear at present. Notably, in a newly-identified human prion disease termed variably protease-sensitive prionopathy, we found a new PrPSc that shares the immunoreactive behavior and fragmentation with iPrPC 11, 12. Moreover, we recently demonstrated that iPrPC is the main species that interacts with amyloid-&beta; protein in Alzheimer disease13. In the same study, these methods were used to isolate Abeta aggregates and oligomers in Alzheimer's disease13, suggesting their application to non-prion protein aggregates involved in other neurodegenerative disorders.

A new species of cellular prion protein (PrPC) has recently been identified in uninfected human brains using the methods described here. These methods can be used to isolate various PrP species, while some of them are also useful in isolating other misfolded protein aggregates from human brains.

Isolamento di oligomeri PrP solubili e insolubili nel cervello umano normale

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform ...

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay

Neuroplasticity is an inherent feature of the enteric nervous system and gastrointestinal (GI) innervation under pathological conditions. However, the pathophysiological role of neuroplasticity in GI disorders remains unknown. Novel experimental models which allow simulation and modulation of GI neuroplasticity may enable enhanced appreciation of the contribution of neuroplasticity in particular GI diseases such as pancreatic cancer (PCa) and chronic pancreatitis (CP). Here, we present a protocol for simulation of pancreatic neuroplasticity under in vitro conditions using newborn rat dorsal root ganglia (DRG) and myenteric plexus (MP) neurons. This dual-neuron approach not only permits monitoring of both organ-intrinsic and -extrinsic neuroplasticity, but also represents a valuable tool to assess neuronal and glial morphology and electrophysiology. Moreover, it allows functional modulation of supplied microenvironmental contents for studying their impact on neuroplasticity. Once established, the present neuroplasticity assay bears the potential of being applicable to the study of neuroplasticity in any GI organ.

Simulating Pancreatic Neuroplasticity: In Vitro Dual-neuron Plasticity Assay

Neuronal plasticity is an increasingly recognized, but insufficiently understood feature of the gastrointestinal (GI) tract. Here, in the example of human pancreatic disorders, we present an in vitro neuroplasticity assay for the study of neuronal plasticity in the GI tract at both morphological and functional level.

Simulazione pancreatica neuroplasticità:<em&gt; In Vitro</em&gt; Dual-neurone Plasticità Assay

Neuroplasticity is an inherent feature of the enteric nervous system and gastrointestinal (GI) innervation under pathological conditions. However, the ...

Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease

M&#252;ller cells are the principal glial cells of the retina. Their end-feet form the limits of the retina at the outer and inner limiting membranes (ILM), and in conjunction with astrocytes, pericytes and endothelial cells they establish the blood-retinal barrier (BRB). BRB limits material transport between the bloodstream and the retina while the ILM acts as a basement membrane that defines histologically the border between the retina and the vitreous cavity. Labeling M&#252;ller cells is particularly relevant to study the physical state of the retinal barriers, as these cells are an integral part of the BRB and ILM. Both BRB and ILM are frequently altered in retinal disease and are responsible for disease symptoms.
There are several well-established methods to study the integrity of the BRB, such as the Evans blue assay or fluorescein angiography. However these methods do not provide information on the extent of BRB permeability to larger molecules, in nanometer range. Furthermore, they do not provide information on the state of other retinal barriers such as the ILM. To study BRB permeability alongside retinal ILM, we used an AAV based method that provides information on permeability of BRB to larger molecules while indicating the state of the ILM and extracellular matrix proteins in disease states. Two AAV variants are useful for such study: AAV5 and ShH10. AAV5&#160;has a natural tropism for photoreceptors but it cannot get across to the outer retina when administered into the vitreous when the ILM is intact (i.e., in wild-type retinas). ShH10 has a strong tropism towards glial cells and will selectively label M&#252;ller glia in both healthy and diseased retinas. ShH10 provides more efficient gene delivery in retinas where ILM is compromised. These viral tools coupled with immunohistochemistry and blood-DNA analysis shed light onto the state of retinal barriers in disease.

To investigate the blood-retinal barrier permeability and the inner limiting membrane integrity in animal models of retinal disease, we used several adeno-associated virus (AAV) variants as tools to label retinal neurons and glia. Virus mediated reporter gene expression is then used as an indicator of retinal barrier permeability.

Utilizzando virus adeno-associati come strumento per studiare le barriere della retina nella malattia

M&#252;ller cells are the principal glial cells of the retina. Their end-feet form the limits of the retina at the outer and inner limiting membranes ...

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Birth asphyxia, which causes hypoxic-ischemic encephalopathy (HIE), accounts for 0.66 million deaths worldwide each year, about a quarter of the world&#8217;s 2.9 million neonatal deaths. Animal models of HIE have contributed to the understanding of the pathophysiology in HIE, and have highlighted the dynamic process that occur in brain injury due to perinatal asphyxia. Thus, animal studies have suggested a time-window for post-insult treatment strategies. Hypothermia has been tested as a treatment for HIE in pdiglet models and subsequently proven effective in clinical trials. Variations of the model have been applied in the study of adjunctive neuroprotective methods and piglet studies of xenon and melatonin have led to clinical phase I and II trials1,2. The piglet HIE model is further used for neonatal resuscitation- and hemodynamic studies as well as in investigations of cerebral hypoxia on a cellular level. However, it is a technically challenging model and variations in the protocol may result in either too mild or too severe brain injury. In this article, we demonstrate the technical procedures necessary for establishing a stable piglet model of neonatal HIE. First, the newborn piglet (&#60; 24 hr old, median weight 1500 g) is anesthetized, intubated, and monitored in a setup comparable to that found in a neonatal intensive care unit. Global hypoxia-ischemia is induced by lowering the inspiratory oxygen fraction to achieve global hypoxia, ischemia through hypotension and a flat trace amplitude integrated EEG (aEEG) indicative of cerebral hypoxia. Survival is promoted by adjusting oxygenation according to the aEEG response and blood pressure. Brain injury is quantified by histopathology and magnetic resonance imaging after 72 hr.

Hypoxic-ischemic encephalopathy following perinatal asphyxia can be studied using animal models. We demonstrate the procedures necessary for establishing a piglet model of neonatal hypoxic-ischemic encephalopathy.

Un modello di Piglet neonatale Hypoxic-ischemica Encefalopatia

Birth asphyxia, which causes hypoxic-ischemic encephalopathy (HIE), accounts for 0.66 million deaths worldwide each year, about a quarter of the ...

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Encephalopathy of prematurity (EoP) is a term that encompasses the central nervous system (CNS) abnormalities associated with preterm birth. To best advance translational objectives and uncover new therapeutic strategies for brain injury associated with preterm birth, preclinical models of EoP must include similar mechanisms of prenatal global injury observed in humans and involve multiple components of the maternal-placental-fetal system. Ideally, models should produce a similar spectrum of functional deficits in the mature animal and recapitulate multiple aspects of the pathophysiology. To mimic human systemic placental perfusion defects, placental underperfusion and/or chorioamnionitis associated with pathogen-induced inflammation in early preterm birth, we developed a model of prenatal transient systemic hypoxia-ischemia (TSHI) combined with intra-amniotic lipopolysaccharide (LPS). In pregnant Sprague Dawley rats, TSHI via uterine artery occlusion on embryonic day 18 (E18) induces a graded placental underperfusion defect associated with increasing CNS damage in the fetus. When combined with intra-amniotic LPS injections, placental inflammation is increased and CNS damage is compounded with associated white matter, gait and imaging abnormalities. Prenatal TSHI and TSHI+LPS prenatal insults meet several of the criteria of an EoP model including recapitulating the intrauterine insult, causing loss of neurons, oligodendrocytes and axons, loss of subplate, and functional deficits in adult animals that mimic those observed in children born extremely preterm. Moreover, this model allows for the dissection of inflammation induced by divergent injury types.

Encephalopathy of prematurity encompasses the central nervous system abnormalities associated with injury from preterm birth. This report describes a clinically relevant rat model of in utero transient systemic hypoxia-ischemia and intra-amniotic lipopolysaccharide administration (LPS) that mimics chorioamnionitis, and the related impact of infectious stimuli and placental underperfusion on CNS development.

Modellazione Encefalopatia di prematurità Utilizzando prenatale ipossia-ischemia con Lipopolisaccaride intra-amniotico in ratti

Encephalopathy of prematurity (EoP) is a term that encompasses the central nervous system (CNS) abnormalities associated with preterm birth. To best ...

Assessing Specificity of Anticancer Drugs In Vitro

A procedure for assessing specificity of anticancer drugs in vitro using cultures containing both tumor and non-tumor cells is demonstrated. The key element is the quantitative determination of a tumor-specific genetic alteration in relation to a universal sequence using a dual-probe digital PCR assay and the subsequent calculation of the proportion of tumor cells. The assay is carried out on a culture containing tumor cells of an established line and spiked-in non-tumor cells. The mixed culture is treated with a test drug at various concentrations. After the treatment, DNA is prepared directly from the survived adhesive cells in wells of 96-well plates using a simple and inexpensive method, and subjected to a dual-probe digital PCR assay for measuring a tumor-specific genetic alteration and a reference universal sequence. In the present demonstration, a heterozygous deletion of the NF1 gene is used as the tumor-specific genetic alteration and a RPP30 gene as the reference gene. Using the ratio NF1/RPP30, the proportion of tumor cells was calculated. Since the dose-dependent change of the proportion of tumor cells provides an in vitro indication for specificity of the drug, this genetic and cell-based in vitro assay will likely have application potential in drug discovery. Furthermore, for personalized cancer-care, this genetic- and cell-based tool may contribute to optimizing adjuvant chemotherapy by means of testing efficacy and specificity of candidate drugs using primary cultures of individual tumors.

Assessing Specificity of Anticancer Drugs In Vitro

The goal of this protocol is to assess specificity of anticancer drugs in vitro using mixed cultures containing both tumor and non-tumor cells.

Valutare Specificità di farmaci antitumorali<em&gt; In Vitro</em

A procedure for assessing specificity of anticancer drugs in vitro using cultures containing both tumor and non-tumor cells is demonstrated. The key ...

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Recently-developed cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs correct surface expression and/or function of the mutant CFTR channel in subjects with cystic fibrosis (CF). Identification of subjects that may benefit from these drugs is challenging because of the extensive heterogeneity of CFTR mutations, as well as other unknown factors that contribute to individual drug efficacy. Here, we describe a simple and relatively rapid assay for measuring individual CFTR function and response to CFTR modulators in vitro. Three dimensional (3D) epithelial organoids are grown from rectal biopsies in standard organoid medium. Once established, the organoids can be bio-banked for future analysis. For the assay, 30-80 organoids are seeded in 96-well plates in basement membrane matrix and are then exposed to drugs. One day later, the organoids are stained with calcein green, and forskolin-induced swelling is monitored by confocal live cell microscopy at 37 &#176;C. Forskolin-induced swelling is fully CFTR-dependent and is sufficiently sensitive and precise to allow for discrimination between the drug responses of individuals with different and even identical CFTR mutations. In vitro swell responses correlate with the clinical response to therapy. This assay provides a cost-effective approach for the identification of drug-responsive individuals, independent of their CFTR mutations. It may also be instrumental in the development of future CFTR modulators.

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

This protocol describes an assay for measuring CFTR function and CFTR modulator responses in cultured tissue from subjects with cystic fibrosis (CF). Biopsy-derived intestinal organoids swell in a cAMP-driven fashion, a response that is defective (or strongly reduced) in CF organoids and can be restored by exposure to CFTR modulators.

Forskolin indotta Gonfiore intestinale organoidi: An<em&gt; In Vitro</em&gt; Test per la valutazione della risposta farmacologica nella fibrosi cistica pazienti

Recently-developed cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs correct surface expression and/or function of the mutant ...

Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research

While there have been remarkable advances in hearing research over the past few decades, there is still no cure for Sensorineural Hearing Loss (SNHL), a condition that typically involves damage to or loss of the delicate mechanosensory structures of the inner ear. Sophisticated in vitro and ex vivo assays have emerged in recent years, enabling the screening of an increasing number of potentially therapeutic compounds while minimizing resources and accelerating efforts to develop cures for SNHL. Though homogenous cultures of certain cell types continue to play an important role in current research, many scientists now rely on more complex organotypic cultures of murine inner ears, also known as cochlear explants. The preservation of organized cellular structures within the inner ear facilitates the in situ evaluation of various components of the cochlear infrastructure, including inner and outer hair cells, spiral ganglion neurons, neurites, and supporting cells. Here we present the preparation, culture, treatment, and immunostaining of neonatal murine cochlear explants. The careful preparation of these explants facilitates the identification of mechanisms that contribute to SNHL and constitutes a valuable tool for the hearing research community.

Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research

The goal of this protocol is to demonstrate the preparation, culture, treatment, and immunostaining of neonatal murine cochlear explants. The technique can be utilized as an in vitro screening tool in hearing research.

Neonatal Murine Cochlear Explant Technique come un<em&gt; In vitro</em&gt; Strumento di screening nella ricerca acustica

While there have been remarkable advances in hearing research over the past few decades, there is still no cure for Sensorineural Hearing Loss (SNHL), a ...